Insmed to Present at Two Upcoming Investor Conferences
26 Février 2013 - 2:00PM
Marketwired
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company
focused on developing and commercializing inhaled therapies for
patients battling serious orphan lung diseases that are often
life-threatening, today announced that members of Insmed's
management team will be presenting the Company's corporate overview
at the following investor conferences in March.
- The Cowen and Company 33rd Annual Health Care Conference taking
place from March 3-6, 2013 at The Boston Marriott Copley Place in
Boston. Will Lewis, President and Chief Executive Officer of
Insmed, will deliver the corporate presentation on Monday, March
4th at 4:50 p.m. Eastern time.
- The 25th Annual Roth Conference taking place from March 17-20,
2013 at the Ritz- Carlton Laguna Niguel in California. Andrew
Drechsler, Insmed's Chief Financial Officer, will deliver the
corporate presentation on Tuesday, March 19th at 9:30 a.m. Pacific
time.
Live webcasts of Mr. Lewis' and Mr. Drechsler's respective
presentations at the Cowen and Company 33rd Annual Healthcare
Conference and the 25th Annual Roth Conference can be accessed by
visiting the investors section of the company's website at
www.insmed.com. A replay of the webcasts will be archived on the
Insmed website for 90 days following each respective
presentation.
About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious orphan lung
diseases through the development and commercialization of
inhalation therapies in orphan patient populations with critical
unmet needs. Insmed's lead candidate, ARIKACE® or liposomal
amikacin for inhalation, is engineered to deliver a proven and
potent anti-infective directly to the site of serious lung
infections to improve the efficacy, safety and convenience of
treatment for at least two identified patient populations: cystic
fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections
and patients with nontuberculous mycobacteria lung infections
(NTM). Insmed's phase 3 registrational study of ARIKACE in Europe
and Canada completed enrollment and the Company expects top-line
clinical results in mid-2013. Insmed's U.S. phase 2 clinical trial
in patients with NTM is well under way with clinical results
expected in late 2013. For more information, please visit
http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made
pursuant to provisions of Section 21E of the Securities Exchange
Act of 1934. Words, and variations of words, such as "intend",
"expect", "will", "anticipate", "believe", "continue", "propose"
and similar expressions are intended to identify forward-looking
statements. Investors are cautioned that such statements in this
release, including statements relating to the status, results and
timing of results of pre-clinical studies and clinical trials and
pre-clinical and clinical data and the anticipated benefits of
Insmed's products, constitute forward-looking statements which
involve risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements.
Such risks and uncertainties include, without limitation, failure
or delay of U.S. Food and Drug Administration and other regulatory
reviews and approvals, competitive developments affecting our
product development, delays in product development or clinical
trials, patent disputes involving currently developing products,
unexpected regulatory actions, delays or requests, the failure of
future clinical trials, inability to successfully develop our
product candidates or receive necessary regulatory approvals,
inability to make product candidates commercially successful,
changes in anticipated expenses, and other risks and challenges
detailed in our filings with the U.S. Securities and Exchange
Commission, including our Annual Report on Form 10-K for the year
ended December 31, 2011 and our Quarterly Report on Form 10-Q for
the quarter ended September 30, 2012. Investors are cautioned not
to place undue reliance on any forward-looking statements which
speak only as of the date of this release. We undertake no
obligation to update these forward-looking statements to reflect
events or circumstances or changes in our expectations.
Investor Relations Contact: LHA Anne Marie Fields Senior
Vice President 212-838-3777 afields@lhai.com Bruce Voss Managing
Director 310-691-7100 bvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024